CYTRX CORP. is engaged in the development and commercialization of pharmaceutical related products and services including human therapeutics focused on high-value critical- care therapies.
An exciting industry consisting of companies who develop new drugs to combat such diseases as cancer and other life-threatening diseases. Some may also participate in gene therapy. These firms either bring new drugs to the market themselves (which is a grueling process) or they sell their technology to bigger pharmaceutical companies.
|
| Totals |
Company |
Industry |
| Sales: |
$0.3 Mil |
$96,376.7 Mil |
| Market Cap: |
$18.8 Mil |
$441,494.0 Mil |
| Analysts Recommendation: |
Strong Buy |
Buy |
|
|
| Averages |
Company |
Industry |
 |
| Growth |
| Historic Revenue: |
150.0% |
93.1% |
| Estimated Revenue: |
N/A |
13.8% |
| Historic Earnings: |
N/A |
(8.3%) |
| Estimated Earnings: |
N/A |
15.0% |
| Stock Price (1 Year): |
(68.7%) |
70.0% |
| Cash per Share: |
(53.4%) |
12.5% |
| Dividend: |
N/A |
N/A |
| Price |
| Trailing PE: |
N/A |
N/A |
| Forward PE: |
N/A |
25.9 |
| Price-to-Sales: |
75.4 |
N/A |
| Price-to-Book: |
.9 |
4.5 |
| Dividend Yield: |
N/A |
N/A |
| Market Cap: |
$18.8 Mil |
$9,811.0 Mil |
| Operations |
| Net Margin: |
(5,084.0%) |
(513.4%) |
| Gross Margin: |
100.0% |
72.9% |
| Return on Equity: |
(.6) |
(.6) |
| Return on Assets: |
(.6) |
(.3) |
| Balance Sheet |
| Current Ratio: |
8.8 |
5.5 |
| Quick Ratio: |
8.8 |
5.1 |
| Cash Ratio: |
8.3 |
4.0 |
| Debt-to-Equity: |
.1 |
1.2 |
| Interest Coverage: |
.5 |
1.0 |
| Technicals |
| Relative-Strength Index: |
N/A |
46.1 |
|
|
|
